Anti-programmed cell death 1 (PD-1) antibodies are in wide use for the treatment of various cancers, particularly cancers with a high tumor mutation burden (TMB) such as advanced cutaneous melanoma (1–4). This evidence concerns the gene PDCD1 and cutaneous melanoma.